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362Endovascular treatment for symptomatic stent
failures in long-segment chronic total occlusion
of femoropopliteal arteries
Xinrui Yang, MD, Xinwu Lu, MD, PhD, Weimin Li, MD, Ying Huang, MD, PhD, Xintian Huang, MD,
Min Lu, MD, and Mi’er Jiang, MD, Shanghai, China
Objective: The objective of this study was to evaluate the outcomes of the secondary endovascular treatment (SEVT) for
symptomatic recurrences in long-segment chronic total occlusion (CTO) of femoropopliteal arteries (FPAs) and to
investigate the factors affecting the outcomes.
Methods: Data of patients undergoing FPA stent implantation for primary, long-segment (>10 cm) CTO lesions and
receiving endovascular intervention for symptomatic recurrences more than once in our institution from July 1, 2008, to
September 1, 2012, were reviewed. Follow-up results referring to SEVT procedures were analyzed, including primary
patency, limb salvage (LS) rate, technical success rate, and prevalence of procedure-related complications. Primary patency
and LS were analyzed with Kaplan-Meier curves. Univariate and multivariable analyses were performed to identify factors
associated with recurrent restenosis with a Cox proportional hazards model.
Results: Ninety-one patients (mean age, 75.1 years) were included. The indications for SEVT were claudication (38.5%)
and critical limb ischemia (61.5%). Preprocedural ankle-brachial index was 0.37 6 0.16. The median time between initial
endovascular treatment and SEVT was 6.5 months (range, 1.0-24.4 months). The arteries in 63 limbs were totally
occluded. Fractures were found in 30 (18.8%) of the initially placed stents. Successful recanalization was achieved in 82
limbs (90.1%). The mean postprocedural ankle-brachial index was 0.84 6 0.15 in those limbs that were successfully
recanalized. The complication rate was 9.9%. One patient died of cerebral hemorrhage during catheter-directed throm-
bolysis. Other complications included the development of a groin hematoma (n [ 5), distal embolization (n [ 1),
formation of a femoral pseudoaneurysm (n [ 1), and development of acute heart failure (n [ 1). The mean follow-up
period was 11.0 6 5.6 months. The cumulative primary patency rate after SEVT was 66.9% and 52.0% at 12 and
24 months. The LS rate since SEVT was 91.2% and 81.1% at 12 and 24 months. The multivariate analysis showed that
stent fracture and stent overlap were independent predictors of recurrent restenosis (hazard ratio, 3.07; 95% conﬁdence
interval, 1.40-6.74; P [ .005; hazard ratio, 4.75; 95% conﬁdence interval, 1.77-12.75; P [ .002).
Conclusions: Endovascular treatment is feasible for FPA stent failure in long-segment CTO. However, SEVT does not
achieve durable patency. Stent fracture and overlap are related to recurrent restenosis. (J Vasc Surg 2014;60:362-8.)Given the special physiologic features of femoropopli-
teal arteries (FPAs), lesions are prone to be diffuse,
complex, and occlusive. Advanced disease in FPAs with
long-segment (>10 cm) chronic total occlusion (CTO) is
common. With improvements in endovascular hardware
and operator experience, endovascular treatment (EVT)
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nical success rate of EVT for CTO of the FPAs has reached
nearly 90% with new techniques and device2,3; stents are
frequently used in complex lesions to treat signiﬁcant
recoil, ﬂow-limiting dissection, or residual stenosis after
angioplasty.
Although acute outcomes of stent implantation are
satisfactory, restenosis is a major concern, with rates
ranging from 20% to 63.5% after 1 year.4-7 Many patients
may need a secondary intervention. The management of
this condition is challenging, with a high recurrence rate af-
ter treatment of in-stent restenosis (ISR). Tosaka et al8
have evaluated the outcomes of treating ISR of FPAs
with balloon angioplasty and reported recurrent ISR rates
of 49.9% to 84.8% at 2 years. However, limited information
is available on the clinical outcomes of secondary EVT
(SEVT) for long-segment CTO, for which the expected
occurrence of ISR is high.4,5,9,10 In addition, although
angiographic restenotic patterns have been shown to be
important factors in recurrent ISR,8,11 the procedural char-
acteristics of the initial EVT (IEVT) associated with the
outcomes after the SEVT have been poorly described in
the literature.8,12,13 Thus, this study aimed to evaluate
Table I. Baseline clinical characteristics
No. (%)
Age, years 75.1 6 7.7
Male 63 (69.2)
Smoker 52 (57.1)
DM 69 (75.8)
HTN 70 (76.9)
HLP 36 (39.6)
CRI 14 (15.4)
CAD 32 (35.2)
CVD 16 (17.6)
Warfarin 4 (4.4)
Indication
Claudication 35 (38.5)
Rest pain 42 (46.2)
Ulcer 8 (8.8)
Gangrene 6 (6.6)
ABI 0.37 6 0.16
ABI, Ankle-brachial index; CAD, coronary artery disease; CRI, chronic
renal insufﬁciency was deﬁned as serum creatinine concentration >1.5
mg/dL; CVD, cerebrovascular disease was deﬁned as a hospital or neurol-
ogist report with the diagnosis of transient ischemic attack or ischemic stroke;
DM, diabetes mellitus; HLP, hyperlipidemia was deﬁned as total cholesterol
concentration >5.72 mmol/L or triglyceride level >1.70 mmol/L; HTN,
hypertension.
Smoker was deﬁned as current or past smoker in last 10 years. Continuous
data are presented as the mean 6 standard deviation; categorical data are
given as the number (%).
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treatment of long-segment CTO and to investigate the fac-
tors affecting these outcomes.
METHODS
Study design. A retrospective review was conducted
from a concurrently maintained database to identify all
patients who underwent a successful EVT for FPA lesions
between July 1, 2008, and September 1, 2012. Patients
who underwent SEVT procedures were identiﬁed. Pa-
tients’ medical records and angiograms were thoroughly
reviewed to identify occurrences of SEVT of primary
long-segment CTO for recurrent symptoms with an
identiﬁed ISR. Asymptomatic patients with duplex-
identiﬁed ISR alone or patients with a history of bypass
surgery in the target limb before the IEVT were excluded.
Baseline clinical characteristics and anatomic and proce-
dural details of the IEVT and SEVT were collected from
the medical records and angiograms. The study protocol
was approved by the ethics committee of Shanghai Ninth
People’s Hospital.
Endovascular procedure for ISR. Each of the pa-
tients who underwent endovascular procedures in this
study was treated with local anesthesia by experienced
vascular surgeons in an interventional suite. The common
access was a retrograde puncture from the contralateral
femoral artery. Retrograde transpopliteal or infrapopliteal
access was used when the “crossover” approach failed to
cross the lesions. After the introducer sheath was inserted,
80 IU/kg heparin sodium was administered to achieve an
activated clotting time of 250 to 300 seconds in all pa-
tients. The lesions were crossed intraluminally with a
0.035- or 0.018-inch guidewire. After being successfully
crossed, the lesions were treated by angioplasty. The
balloon diameter and length were determined by the
operator by angiography. Catheter-directed thrombolysis
(CDT) and stent implantation were used as adjunctive
treatments in cases of thrombosis, residual stenosis, or
ﬂow-limiting dissection. The iliac artery and runoff vessels
were also treated if signiﬁcant lesions were identiﬁed, and
restoring patency of additional runoff vessels was generally
preferred to only one runoff vessel. All patients without
contraindications received oral aspirin (100 mg/d) indeﬁ-
nitely and cilostazol (200 mg/d) for at least 6 months after
hospital discharge. However, clopidogrel was administered
to patients with coronary or carotid artery disease treated
with stent placement.
Follow-up. A clinical follow-up examination was per-
formed with ofﬁce visits at 1, 3, and 6 months and every
6 months thereafter. The clinical examination, ankle-
brachial index (ABI), and ultrasound examination of each
patient were recorded. Follow-up computed tomography
or magnetic resonance angiography was performed in cases
of worsened symptoms or if restenosis greater than 50%
was detected on a Doppler scan.
Outcomes and deﬁnitions. The follow-up results
were analyzed, including primary patency, limb salvage
(LS) rate, technical success rate, and prevalence ofprocedure-related complications. Restenosis was deﬁned by
the identiﬁcation of a peak systolic velocity ratio of greater
than 2.5 on a duplex ultrasound examination or greater
than 50% stenosis by angiography. In our vascular labora-
tory, a peak systolic velocity ratio greater than 2.5 repre-
sents 50% to 75% vessel stenosis.14 Reintervention was
undertaken when symptoms recurred and a restenosis of
greater than 50% was identiﬁed on imaging studies.
Technical success was deﬁned as the restoration of straight-
line ﬂow to the foot, with less than 30% residual stenosis.
LS was deﬁned as freedom from above-the-ankle amputa-
tion. Long-segment CTO lesions were deﬁned as a length
of obstruction more than 10 cm and symptoms lasting
more than 30 days.15 Stent fractures were classiﬁed ac-
cording to the ﬁve-type classiﬁcation system.16
Statistical analysis. Continuous data were presented
as the mean 6 standard deviation. Continuous variables
were compared with the Student t test. Primary patency
and LS were analyzed with Kaplan-Meier curves and the
log-rank test. Univariate and multivariable analyses were
performed to identify factors associated with recurrent
restenosis with a Cox proportional hazards model. Vari-
ables associated with outcomes by the univariate analysis
(P < .1) were included in the multivariable regression
model. Before the multivariable analysis, relationships be-
tween signiﬁcant variables in the univariate analysis were
also tested. An a value of .05 corresponding to P ¼ .05
and 95% conﬁdence intervals were used as criteria for sta-
tistical signiﬁcance. Statistical computations were per-
formed with SPSS Statistics software (version 19; SPSS Inc,
Armonk, NY).
Table II. Characteristics of de novo lesions and details of
initial stent implantation procedures
Lesion length, cm 24.9 6 8.5
Number of runoff vessels
0 7 (7.7)
1 44 (48.2)
2 22 (24.2)
3 18 (19.8)
Calciﬁcationa 30 (33.0)
Stent location
Proximalb 36 (39.6)
Popliteal 39 (42.9)
Number of stents 160
Stent diameter, mm 5.77 6 0.46
Total stent length, cm 20.1 6 9.7
Overlap 32 (35.2)
Postdilation 22 (24.2)
Continuous data are presented as the mean 6 standard deviation; cate-
gorical data are given as the number (%).
aCalciﬁcation was included when it was >50% of the total length of the
occlusion on computed tomography or magnetic resonance angiography
imaging.
bProximal region was deﬁned as a 10-mm segment that began from ostium
to distal of superﬁcial femoral artery.
Table III. The types of initial stents and fracture types
Stent type IEVT I/II/III/IV/Va
S.M.A.R.T (Cordis) 32 (20.0) 4/6/0/0/0
Zilver (Cook) 10 (6.25) 3/0/0/0/0
Protégé GPS (ev3) 10 (6.25) 0/2/0/0/0
Luminexx (Bard) 2 (1.25) 0/0/0/0/0
LifeStent (Bard) 10 (6.25) 0/2/2/0/0
Protégé EverFlex (ev3) 88 (55.0) 3/2/4/2/0
Others (balloon-expandable stent) 8 (5.0) 0/0/0/0/0
Data are presented as number (%).
aTypes of stent fracture: I, only a single strut; II, multiple struts; III,
complete transverse fracture without displacement; IV, complete transverse
linear fracture with stent displacement; and V, spiral fracture.
Table IV. The angiographic characteristics and details of
SEVT procedures
Restenosis pattern
Focal (#50 mm) 8 (8.8)
Diffuse (>50 mm) 20 (22.0)
Totally occluded 63 (69.2)
Number of runoff vessels
0 6 (6.6)
1 40 (44)
2 28 (30.8)
3 17 (18.7.8)
Treated region
FPA only 34 (37.4)
Iliac artery 12 (13.2)
Runoff arteries 41 (45.1)
Both iliac and runoff arteries 4 (4.4)
Adjunctive therapy
Stent implantation 41 (45.1)
CDT 24 (26.4)
Atherectomy 2 (2.2)
CDT, Catheter-directed thrombolysis; FPA, femoropopliteal arteries; SEVT,
secondary endovascular treatment.
Data are presented as number (%).
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Baseline clinical characteristics. From July 1, 2008, to
September 1, 2012, a total of 775 endovascular procedures
were performed in 522 limbs (492 patients) because of
FPA disease, including 261 SEVT procedures. Of the total
cohort, 178 patients (189 limbs) were treated with FPA
stents for primary long-segment CTO. By review of medi-
cal records and angiograms of patients who underwent the
SEVT procedures, 91 patients (91 limbs) who met the in-
clusion criteria were included in our study. The reasons for
excluding 170 SEVT procedures included unmatched pri-
mary lesions and initial procedures in 157 limbs, absence of
symptoms in 10 limbs, and history of bypass surgery in 3
limbs. The mean age was 75.1 6 7.7 years. Indications for
the SEVT were claudication (38.5%) and critical limb
ischemia (CLI; 61.5%). The mean preprocedural ABI was
0.376 0.16. The baseline clinical characteristics are listed in
Table I. The median time between the IEVT and SEVTwas
6.5 months (range, 1.0-24.4 months). Thirty-nine (42.9%)
SEVT procedures were performed within 180 days after
initial stent implantation.
Characteristics of IEVT procedures. Claudication
and CLI were indications for the IEVT in 57 patients
(62.6%) and 34 patients (37.4%), respectively. The charac-
teristics of primary lesions and details of initial stent implan-
tation procedures are presented in Table II. The mean
preprocedural ABI was 0.44 6 0.17. After successful IEVT
procedures, the mean increase in ABI was 0.396 0.17. The
mean lesion length was 24.96 8.5 cm. The number of limbs
and patients with poor runoff conditions (#1 vessels) were
51 (56.1%). Calciﬁcations were found in 30 limbs (33.0%).
The mean number of stents used was 1.8 6 0.7 per limb
(range, 1-4). Themean stent diameter was 5.776 0.46mm,
and the overall stent length was 20.1 6 9.7 cm. The stenttypes and frequencies of use are presented in Table III. Fifty-
ﬁve limbs (60.4%) were treated with multiple stents, and 23
of them (41.8%) did not overlap.
Angiographic characteristics and details of SEVT
procedures. The angiographic characteristics and details of
the SEVT procedures are outlined in Table IV. Of the 91
limbs, 63 (69.2%) were totally occluded. The number of
limbs in patients with poor runoff conditions (#1 vessel)
was 46 (50.6%). Fractures were found in 30 initial stents
(18.8%). Complete transverse fractures were found in
eight stents. Details are presented in Table III. Balloon
angioplasty was performed in all limbs. Forty-six stents
were implanted in 41 limbs (45.1%) as an additional
therapy during angioplasty. The number of stents was
2.3 6 0.9 per limb. The overall length of the stents was
23.9 6 10.0 cm. Twenty-four limbs (26.4%) underwent
CDT because of concomitant thrombosis. Two limbs
(2.2%) received atherectomy.
Clinical outcomes. Technical success was achieved in
82 limbs (90.1%). The mean postprocedural ABI was
0.84 6 0.15 (P ¼ .000 compared with presecondary ABI
Fig 1. Cumulative primary patency rate. SE, Standard error. Fig 2. Cumulative limb salvage (LS) rate. SE, Standard error.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 2 Yang et al 365measurements) in patients who underwent successful sec-
ondary revascularization. Technical failure occurred in
eight limbs because of the inability to cross the occluded
stent intraluminally (n ¼ 5) and the failure to restore
straight-line ﬂow to the foot (n ¼ 3). In addition, one
patient died of cerebral hemorrhage during CDT. Other
complications included the development of a groin hema-
toma in ﬁve patients and the development of distal
embolization, formation of a femoral pseudoaneurysm, and
development of acute heart failure in one patient each. The
distal embolism was resolved by CDT plus angioplasty. The
femoral pseudoaneurysm was found during the procedure
and controlled by injecting prothrombin complex and
performing prolonged balloon angioplasty. The patient
who suffered acute heart failure recovered after medical
therapy. The complication rate was 9.9%.
Of the eight technical failures of SEVT, two patients
underwent femoral distal bypass surgery. Three patients
received amputation (two, above-the-knee; one, below-
the-knee). Three patients took antiplatelet therapy and un-
derwent EVTs successfully a few months later.
The mean follow-up period was 11.0 6 5.6 months.
Ten patients were lost to follow-up. The cumulative primary
patency rate of the SEVT was 66.9% and 52.0% at 12 and
24 months, respectively (Fig 1). Whether additional stent
implantation was used had no effect on primary patency
(P ¼ .219). During the course of follow-up, 29 limbs lost
primary patency. Twenty-four patients underwent repeated
revascularization to restore the blood supply. Another
ﬁve patients had ischemia that progressed and required
below-the-knee amputation. No additional fractures were
identiﬁed. All eight patients who underwent amputations
developed CLI before SEVT procedures; one presented
with claudication before the IEVT procedure, and theother seven patients had CLI initially. The cumulative LS
rate after the SEVT procedures was 91.2% and 81.1% at
12 and 24 months, respectively (Fig 2). LS rates of patients
for initial claudication and CLI were 97.1% 6 2.8% and
81.2% 6 7.0% at 12 months, respectively (P ¼ .001).
Multivariate analysis. The risk factors for recurrent
restenosis were examined by the Cox hazard model.
Baseline clinical characteristics (age, sex, hypertension,
hyperlipidemia, diabetes mellitus, smoker, chronic renal
insufﬁciency, coronary artery disease, cerebrovascular dis-
ease, CLI, warfarin administration, ABI, and stent
failure <180 days), characteristics of primary lesions (lesion
length, poor runoff vessels, and calciﬁcation), restenosis
pattern, and characteristics of IEVT and SEVT (stent loca-
tion, multiple stents, stent length and diameter, stent frac-
ture, overlap, and additional therapy) with P < .1 on Cox
univariate models were tested by correlation analysis. The
analysis showed that the presence of CLI and ABI were
signiﬁcantly related (P ¼ .00). Lesion length was not asso-
ciated with stent fracture (P ¼ .77) or overlap (P ¼ .06),
but its relationships with stent length (P ¼ .00) and multi-
ple stents (P ¼ .01) were statistically signiﬁcant. Finally, the
presence of CLI, lesion length, stent fracture, and stent
overlap were entered into the multivariable Cox regression
model (Table V). The multivariate analysis showed that
stent fracture and stent overlap were independent pre-
dictors of recurrent restenosis (hazard ratio, 3.07; 95%
conﬁdence interval, 1.40-6.74; P ¼ .005, and hazard ratio,
4.75; 95% conﬁdence interval, 1.77-12.75; P ¼ .002,
respectively).
DISCUSSION
Historically, midterm results of EVTs to treat resteno-
sis of long-segment FPA stenoses and occlusions have been
Table V. Univariate and multivariate analysis of recurrent restenosis
Variables
Univariate analysis Multivariate analysis (forward LR)
HR (95% CI) P value HR (95% CI) P value
ABI 0.13 (0.01-1.37) .088
CLI 2.38 (0.96-5.92) .062
Lesion length 1.01 (1.00-1.01) .013
Total stent length 1.00 (1.00-1.01) .067
Stent fracture 1.92 (0.91-4.05) .086 3.07 (1.40-6.74) .005
Multiple stents 3.50 (0.83-14.77) .086
Stent overlap 3.13 (1.26-7.76) .014 4.75 (1.77-12.75) .002
ABI, Ankle-brachial index; CI, conﬁdence interval; CLI, critical limb ischemia; HR, hazard ratio; LR, linear regression.
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ported for treatment of primary lesions.17,18 The recurrent
restenosis rate is high, with primary patency of 66.9% and
52.0% at 12 and 24 months, respectively. Neither repeated
stent implantation nor balloon angioplasty showed beneﬁts
of avoiding recurrent restenosis in this study. The treat-
ment options for the management of ISR are numerous,
and the optimal technique is unknown. Traditional balloon
angioplasty, cutting balloon angioplasty, and repeated stent
implantation (bare-metal stent) are often inadequate to
treat ISR.8,19,20 Emerging techniques and devices show
promising avenues. Stabile et al13 reported a 92.1% primary
patency rate at 12 months after treating ISR with a drug-
eluting balloon. Data from the Zilver PTX (a drug-
eluting stent) registry21 show freedom from target lesion
revascularization at 1 year in 78% of patients. The 12-
month results of a SALVAGE study22 show a low rate of
target lesion revascularization of 17.4% by use of an exci-
mer laser with stent grafts. Although initial results are
encouraging, judgment should be reserved until results
from large randomized controlled trials have been
validated.
Although reinterventions were needed in several
patients to restore blood supply and to relieve symptoms,
favorable acute outcomes and minimally invasive features
of an EVT make it an alternative to treat FPA stent failure
in cases of long-segment CTO with a high technical success
rate and few severe complications. Moreover, the LS rates of
patients with initial claudication andCLIwere 97.1%6 2.8%
and 81.2% 6 7.0% at 12 months, respectively. Increasing
blood ﬂow after reintervention might positively affect the
eradication of infection and the healing of ulcers and surgical
wounds,23 thus simultaneously allowing the formation of
collateral vessels for extra blood supply.
Stent fracture has been an important issue since stent
implantation became widely used to treat FPA lesions.
Stent fractures are related to high rates of restenosis.24-26
Therefore, second-generation nitinol stents were devel-
oped. These stents are more ﬂexible and fracture resistant.
Resilient (LifeStent)5 and Durability (EverFlex)27 studies
showed a signiﬁcant decrease in stent fractures. In the cur-
rent study, the total stent fracture rate was 18.8%; severe
fracture with complete separation of stent segments8 is
rare but has occurred in both stent types mentioned. TheEverﬂex (ev3) is commonly used, having a fracture rate
of 15.9%, higher than previous data. This ﬁnding implies
that limitations in stent design are not the only factors in
fractures. The degree of the lesion, location of the stent,
and inappropriate stent release28 might also affect the
integrity of stents. Stent fracture is associated with recur-
rent restenosis after ISR treatment according to our data,
suggesting that stent fracture has a long-term effect on
stent patency.
In general, multiple stents are deployed in an overlap-
ping manner to treat long lesions,5,29 which is also com-
mon in cases of long-segment CTO. Stent overlap is
related to poor patency, which is difﬁcult to explain
because the literature is limited to reports on the relation-
ship between overlapping stents and clinical outcomes.30
Potential reasons for poor patency are as follows. (1) Over-
lapping portions of stents have twice the axial rigidity of
those regions that do not overlap,31 resulting in a compres-
sion effect at the margins of the overlapping stent and
added stress on the vessel. More stress increases injury.
(2) Stent overlap can also change the ﬂexibility of the stent
as a whole, increasing the risk of stent fracture.24,32 (3)
Increased strut thickness and contact surface may cause
more vascular injury.33 (4) Stent overlap usually implies
diffuse and extensive dissection or residual stenosis, which
cannot be resolved by a single stent. Considering this risk
factor, several points might be noted during EVT proce-
dures. First, low-proﬁle, long-length balloon dilation for
long-segment lesions is recommended to reduce diffuse
dissection and consequently to shorten stent length. Sec-
ond, the application of CDT and atherectomy devices
may help decrease the range of lesions that require treat-
ment with a stent. In addition, long and ﬂexible stents
are preferred for such challenging FPA lesions. The
second-generation slotted tube nitinol stents with a
maximal length of 20 cm have been widely used in clinical
practice. New concepts of stents, such as interwoven
closed-cell SUPERA stents and alternating helix SAMBA
stents, have been developed, combining good ﬂexibility
and high resistance,28 but await publication of a complete
data set.
It was noted that 22 of 57 patients (38.6%) who were
initially treated for claudication presented with CLI at the
time of ISR. The main reason for this CLI might be
JOURNAL OF VASCULAR SURGERY
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tients. Sixteen patients who presented with claudication
initially received CDT during the SEVT procedures, and
12 of these patients presented with CLI at the time of
restenosis. This aggravated symptom might be associated
with the extent of the occlusion of preexisting vessels. In
addition, patient preference played a part in this CLI.
Despite routine follow-up, patients with greater than 50%
restenosis but no symptoms might ask for medical therapy
instead of SEVT. With disease progression, lesions became
more diffuse and prone to thrombosis.
Limitations. This study has several limitations. First, it
was a retrospective, single-center analysis with small sample
size, which makes the results underpowered. Second, it
lacked a control group of patients who underwent surgical
or medical therapy after initial endovascular failure because
of the study design. Third, the different stents used may
have affected the results. The variety of stents used in a
single vessel made it difﬁcult to explore such a potential
effect.
CONCLUSIONS
Despite its limitations, this study reported EVTs to
treat FPA stent failure in cases of long-segment CTO. It
also identiﬁed the relationship between overlapping stents
and clinical outcomes. EVTs are feasible for the treatment
of FPA stent failure in cases of long-segment CTO with
satisfactory technical success and acceptable LS rates. How-
ever, SEVT does not achieve durable patency. Stent frac-
ture and overlap are related to recurrent restenosis. Large
randomized controlled trials and the cost-effectiveness
analysis of emerging devices (eg, drug-eluting devices, exci-
mer laser, and stent grafts) and surgical therapies to treat
stent failure are required. In addition, further studies on
the biomechanical inﬂuence and pathology of overlapping
stents in FPA segments are warranted.
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